Serum leucine-rich alpha-2 glycoprotein levels for predicting active ultrasonographic findings in intestinal lesions of patients with Crohn's disease in clinical remission

被引:5
|
作者
Nasuno, Masanao [1 ]
Shimazaki, Hiroshi [1 ]
Nojima, Masanori [2 ]
Hamada, Takahito [1 ]
Sugiyama, Kohei [1 ]
Miyakawa, Maki [1 ]
Tanaka, Hiroki [1 ,3 ]
机构
[1] Sapporo IBD Clin, Sapporo, Japan
[2] Univ Tokyo, Inst Med Sci Hosp, Ctr Translat Res, Tokyo, Japan
[3] Sapporo IBD Clin, Yamahana Doctor Town F2,1-18,Minami 19,Nishi 8,Chu, Sapporo, Hokkaido 0640919, Japan
关键词
Crohn's disease; intestinal ultrasonography; leucine-rich alpha-2 glycoprotein; superb microvascular imaging; INFLAMMATORY-BOWEL-DISEASE; ACTIVITY INDEX; ULTRASOUND; VASCULARITY; BIOMARKER; GUIDELINES; CORRELATE; WALL;
D O I
10.1097/MD.0000000000034628
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aimed to investigate the cutoff value of leucine-rich alpha-2 glycoprotein (LRG) in predicting active intestinal ultrasonography (IUS) findings in patients with Crohn's disease (CD) in clinical remission. Data were retrospectively collected from patients with CD evaluated using LRG and undergoing IUS from September 2020 to August 2022. Patients with a Harvey-Bradshaw Index of & LE;4 were included and those who underwent intestinal resection were excluded. Bowel wall thickness and stratification and blood flow signal using superb microvascular imaging (SMI) were used to assess ultrasonography findings. SMI signals were categorized into 4 grades following the Limberg score. Receiver operating characteristic curves were constructed and the area under the curve was calculated to determine the LRG cutoff values for predicting active IUS findings and were compared with those of C-reactive protein. This study included 213 patients. The LRG cutoff values to predict active bowel wall thickness, loss of bowel wall stratification, and SMI of & GE;1, & GE;2, and 3 were 14.6 & mu;g/mL, 14.6 & mu;g/mL, 14.6 & mu;g/mL, 14.6 & mu;g/mL, and 16.9 & mu;g/mL, respectively, with significantly higher areas under the curve in SMI of & GE;1 and 3 than in C-reactive protein. The best LRG cutoff value for predicting active IUS findings was 14.6 & mu;g/mL in patients with CD in clinical remission, suggesting that LRG is better than C-reactive protein for detecting active IUS findings in CD.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] SERUM LEUCINE-RICH ALPHA-2 GLYCOPROTEIN LEVELS FOR PREDICTING ACTIVE ULTRASONOGRAPHIC FINDINGS IN INTESTINAL LESIONS OF PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION
    Nasuno, Masanao
    Shimazaki, Hiroshi
    Nojima, Masanori
    Hamada, Takahito
    Sugiyama, Kohei
    Miyakawa, Maki
    Tanaka, Hiroki
    GASTROENTEROLOGY, 2023, 164 (06) : S1220 - S1220
  • [2] Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission
    Nakamura, Naohiro
    Honzawa, Yusuke
    Ito, Yuka
    Sano, Yasuki
    Yagi, Naoto
    Kobayashi, Sanshiro
    Aoi, Mamiko
    Tomiyama, Takashi
    Tahara, Tomomitsu
    Fukata, Norimasa
    Fukui, Toshiro
    Naganuma, Makoto
    INTESTINAL RESEARCH, 2024,
  • [3] Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn's disease during biological remission
    Nakamura, Naohiro
    Honzawa, Yusuke
    Ito, Yuka
    Sano, Yasuki
    Yagi, Naoto
    Kobayashi, Sanshiro
    Aoi, Mamiko
    Tomiyama, Takashi
    Tahara, Tomomitsu
    Fukata, Norimasa
    Fukui, Toshiro
    Naganuma, Makoto
    INTESTINAL RESEARCH, 2024,
  • [4] Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease
    Abe, Izuru
    Shiga, Hisashi
    Chiba, Hirofumi
    Miyazawa, Teruko
    Oomori, Shinya
    Shimoyama, Yusuke
    Moroi, Rintaro
    Kuroha, Masatake
    Kakuta, Yoichi
    Kinouchi, Yoshitaka
    Masamune, Atsushi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (09) : 1741 - 1748
  • [5] Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn's disease small bowel lesion in capsule endoscopy
    Omori, Teppei
    Koroku, Miki
    Murasugi, Shun
    Ito, Ayumi
    Yonezawa, Maria
    Nakamura, Shinichi
    Tokushige, Katsutoshi
    INTESTINAL RESEARCH, 2024, 22 (04)
  • [6] Leucine-rich Alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn's disease
    Tashiro, Taku
    Shinzaki, Shinichiro
    Yoshihara, Takeo
    Tsujii, Yuri
    Asakura, Akiko
    Amano, Takahiro
    Tani, Mizuki
    Otake-Kasamoto, Yuriko
    Uema, Ryotaro
    Tsujii, Yoshiki
    Inoue, Takahiro
    Ogino, Takayuki
    Iijima, Hideki
    Hayashi, Yoshito
    Takehara, Tetsuo
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [7] Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
    Komatsu, Moeko
    Sagami, Shintaro
    Hojo, Aya
    Karashima, Ryo
    Maeda, Masa
    Yamana, Yoko
    Serizawa, Kanade
    Umeda, Satoko
    Asonuma, Kunio
    Nakano, Masaru
    Hibi, Toshifumi
    Matsuda, Takahisa
    Kobayashi, Taku
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (04) : 658 - 666
  • [8] Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease
    Kawamura, Tatsuya
    Yamamura, Takeshi
    Nakamura, Masanao
    Maeda, Keiko
    Sawada, Tsunaki
    Ishikawa, Eri
    Iida, Tadashi
    Mizutani, Yasuyuki
    Ishikawa, Takuya
    Kakushima, Naomi
    Furukawa, Kazuhiro
    Ohno, Eizaburo
    Honda, Takashi
    Kawashima, Hiroki
    Ishigami, Masatoshi
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (02) : 245 - 253
  • [9] Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes
    Krienke, Michelle
    Kralisch, Susan
    Wagner, Leonie
    Toenjes, Anke
    Miehle, Konstanze
    BIOMOLECULES, 2024, 14 (11)
  • [10] Editorial: Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
    Mitchell, Anna
    Swaminathan, Akhilesh
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (05) : 895 - 896